These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 1737346)

  • 1. Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial.
    Ernstoff MS; Gooding W; Nair S; Bahnson RR; Miketic LM; Banner B; Day R; Whiteside T; Titus-Ernstoff L; Kirkwood JM
    Cancer Res; 1992 Feb; 52(4):851-6. PubMed ID: 1737346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma.
    Ernstoff MS; Nair S; Bahnson RR; Miketic LM; Banner B; Gooding W; Day R; Whiteside T; Hakala T; Kirkwood JM
    J Clin Oncol; 1990 Oct; 8(10):1637-49. PubMed ID: 2120392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters.
    Schwaab T; Heaney JA; Schned AR; Harris RD; Cole BF; Noelle RJ; Phillips DM; Stempkowski L; Ernstoff MS
    J Urol; 2000 Apr; 163(4):1322-7. PubMed ID: 10737537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A study of effective administration of recombinant interferon-gamma in renal cell carcinoma regarding immunological influence on peripheral blood lymphocytes].
    Kawata N; Ono M; Kodama M; Yamanaka Y; Hirakata H; Hirano D; Fuse T; Takimoto Y
    Hinyokika Kiyo; 1995 Jan; 41(1):21-6. PubMed ID: 7900565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/II trial of recombinant gamma-interferon in patients with renal cell carcinoma: immunologic and biologic effects.
    Rinehart JJ; Young D; Laforge J; Colburn D; Neidhart J
    J Biol Response Mod; 1987 Jun; 6(3):302-12. PubMed ID: 3110379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer cell cytotoxicity is enhanced by very low doses of rIL-2 and rIFN-alpha in patients with renal cell carcinoma.
    Pavone L; Fanti G; Bongiovanni C; Goldoni M; Alberici F; Bonomini S; Cristinelli L; Buzio C
    Med Oncol; 2009; 26(1):38-44. PubMed ID: 18516705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group.
    De Mulder PH; Oosterhof G; Bouffioux C; van Oosterom AT; Vermeylen K; Sylvester R
    Br J Cancer; 1995 Feb; 71(2):371-5. PubMed ID: 7841054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo biological response to recombinant interferon-gamma during a phase I dose-response trial in patients with metastatic melanoma.
    Kirkwood JM; Ernstoff MS; Trautman T; Hebert G; Nishida Y; Davis CA; Balzer J; Reich S; Schindler J; Rudnick SA
    J Clin Oncol; 1990 Jun; 8(6):1070-82. PubMed ID: 2112184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma.
    Bukowski RM; Sharfman W; Murthy S; Rayman P; Tubbs R; Alexander J; Budd GT; Sergi JS; Bauer L; Gibson V
    Cancer Res; 1991 Aug; 51(16):4199-205. PubMed ID: 1868441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological changes in peripheral blood mononuclear cells of patients with metastatic renal cell carcinoma after low doses of subcutaneous immunotherapy with IFN-alpha-2b and IL-2.
    Moltó L; Carballido J; Manzano L; Martinez-Martin B; Esquivel F; Chafer J; Olivier C; Alvarez-Mon M
    J Immunother; 1999 May; 22(3):260-7. PubMed ID: 10335486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunological study of the postoperative adjuvant treatment with interferon gamma in patients with renal cell cancer--measurement of peripheral blood lymphocyte subsets with three color flow cytometry].
    Yasunaga Y; Nishimura K; Miura H; Takatera H; Kuroda H; Kishimoto T; Fujioka H
    Hinyokika Kiyo; 1995 Feb; 41(2):85-92. PubMed ID: 7702012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose interleukin-2 in combination with interferon-alpha effectively modulates biological response in vivo.
    Schneekloth C; Körfer A; Hadam M; Lopez Hänninen E; Menzel T; Schomburg A; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
    Acta Haematol; 1993; 89(1):13-21. PubMed ID: 7683166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II trial of interferon-beta-serine in patients with renal cell carcinoma: immunological and biological effects.
    Rinehart JJ; Young D; Laforge J; Colborn D; Neidhart JA
    Cancer Res; 1987 May; 47(9):2481-5. PubMed ID: 3567933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretreatment natural killer antigen density correlates to clinical response in tumor patients receiving long-term subcutaneous recombinant interleukin-2 and recombinant interferon-alpha.
    Duensing S; Hadam M; Körfer A; Schomburg A; Menzel T; Grosse J; Kirchner H; Poliwoda H; Atzpodien J
    Mol Biother; 1992 Dec; 4(4):170-3. PubMed ID: 1282326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute effects of single doses of recombinant interferon-gamma on blood cell counts and lymphocyte subsets in patients with advanced renal cell cancer.
    Aulitzky WE; Aulitzky W; Gastl G; Lanske B; Reitter J; Frick J; Tilg H; Berger M; Herold M; Huber C
    J Interferon Res; 1989 Aug; 9(4):425-33. PubMed ID: 2502583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of nephrectomy and interferon administration on immunological parameters in patients with renal cell carcinoma].
    Arima K; Yanagawa M; Sugimura Y; Tochigi H; Kawamura J; Saitoh K; Yamazaki Y; Mori O; Oomoto Y; Nakagawa M
    Hinyokika Kiyo; 1994 Jun; 40(6):469-74. PubMed ID: 8073952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous interleukin-2 and interferon-alpha 2b in patients with metastatic renal cell cancer: the German outpatient experience.
    Kirchner H; Körfer A; Palmer PA; Evers P; De Riese W; Knüver-Hopf J; Hadam M; Goldman U; Franks CR; Poliwoda H
    Mol Biother; 1990 Sep; 2(3):145-54. PubMed ID: 2222898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant interferon alpha and gamma in combination as treatment for metastatic renal cell carcinoma.
    Quesada JR; Evans L; Saks SR; Gutterman JU
    J Biol Response Mod; 1988 Jun; 7(3):234-9. PubMed ID: 3134511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha-2.
    Atzpodien J; Kirchner H; Körfer A; Hadam M; Schomburg A; Menzel T; Deckert M; Franzke A; Volkenandt M; Dallmann I
    Tumour Biol; 1993; 14(6):354-9. PubMed ID: 8265981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunological assessment after radical nephrectomy for renal cell carcinomas pre-treated with interferon-gamma].
    Onishi T; Machida T; Masuda F; Igarashi H
    Hinyokika Kiyo; 1991 Jul; 37(7):671-8. PubMed ID: 1927765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.